Instil Bio, Inc.

Listed Company

TILCIK 0001789769NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthBiological Products, (No Diagnostic Substances)New YorkFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-71.37M

Total Assets

$203.52M

Equity

$113.87M

Shares Out

6.78M

Op. Cash Flow

$-36.62M

Business

Instil Bio, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for oncology. It is advancing AXN-2510/IMM2510, a PD-L1xVEGF bispecific antibody, and has in‑licensed AXN-27M/IMM27M, a CTLA-4 monoclonal antibody, while acquiring additional therapeutic candidates. Key operations include drug discovery and clinical development conducted through its subsidiary Axion Bio and collaborations with ImmuneOnco, with intellectual property and licensing arrangements governing program rights. Clinical development and licensing activities span the United States, Europe, Japan and Greater China (where ImmuneOnco retains rights), with trials conducted in China and other jurisdictions.

Summary from filing dated 2025-03-04

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
In-process research and development	10	10	0	—	—
Research and development	25	12	40	—	—
General and administrative	27	44	48	62	48
Restructuring and impairment charges	17	7	72	23	0
Total operating expenses	79	74	159	226	156
Loss from operations	−79	−74	−159	−226	−156
Interest income	4	7	9	4	80,000
Interest expense	−6	−9	−5	—	—
Other rental income	9	4	0	—	—
Other income (expense), net	212,000	−3	−575,000	−564,000	−1
Net loss	−71	−74	−156	−223	−157
Foreign currency translation	−342,000	168,000	−433,000	9,000	246,000
Unrealized loss on available-for-sale securities, net	−13,000	−48,000	578,000	−415,000	−50,000
Net comprehensive loss	−72	−74	−156	−224	−157
Net loss per share, basic (in dollars per share)	−10.7	−11.39	−24	−34.46	−1.48
Net loss per share, diluted (in dollars per share)	−10.7	−11.39	−24	−34.46	−1.48
Weighted-average shares used in computing net loss per share, basic (in shares)	7	7	7	6	106
Weighted-average shares used in computing net loss per share, diluted (in shares)	7	7	7	6	106

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	7	9	9	44	38
Restricted cash	200,000	2	2	0	—
Marketable securities	70	105	141	—	—
Prepaid expenses and other current assets	3	9	9	8	10
Assets held for sale	112	0	—	—	—
Total current assets	191	124	161	269	464
Property, plant and equipment, net	126,000	129	139	197	122
Operating lease right-of-use assets	238,000	934,000	2	12	0
Accrued rent receivable	8	4	—	—	—
Other long-term assets	4	4	639,000	3	8
Total assets	204	264	326	482	610
Accounts payable	779,000	659,000	1	2	6
Accrued expenses and other current liabilities	4	7	9	30	34
Total current liabilities	5	8	11	33	41
Contingent consideration	0	948,000	5	8	11
Operating lease liabilities, non-current	0	1	3	5	0
Loan payable	85	84	81	72	0
Other long-term liabilities	8,000	83,000	80,000	332,000	20,000
Total liabilities	90	94	100	119	55
Commitments and contingencies (Note 8)	—	—	—	—	—
Preferred stock, par value $0.000001 per share; 10,000,000 shares authorized; zero shares issued and outstanding as of December 31, 2025, and 2024	0	0	0	0	0
Common stock, par value $0.000001 per share; 300,000,000 shares authorized; 6,781,976 and 6,525,887 shares issued and outstanding as of December 31, 2025, and 2024	0	0	0	0	0
Additional paid-in capital	841	825	807	789	757
Accumulated other comprehensive loss	−583,000	−228,000	−348,000	−493,000	−87,000
Accumulated deficit	−726	−655	−581	−425	−202
Total stockholders equity	114	169	226	364	555
Total liabilities and stockholders equity	204	264	326	482	610

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	9	17	18	30	26
Non-cash lease expense	286,000	212,000	640,000	—	—
Foreign exchange remeasurement (gain) loss	−484,000	275,000	−680,000	1	710,000
Impairment of property, plant and equipment	17	4	—	—	—
Impairment of right-of-use assets	0	827,000	8	166,000	—
Change in fair value of contingent consideration	−948,000	−4	−3	−3	294,000
Depreciation	534,000	4	5	6	3
Restructuring costs	−91,000	0	—	—	—
Accretion on invested securities	−37,000	−4	−7	−1	—
Non-cash interest expense	791,000	962,000	1	−198,000	0
Non-cash loss on debt extinguishment	0	415,000	0	—	—
Change in fair value of derivative financial instrument	0	1	1	−1	0
Loss on disposals of property and equipment	0	343,000	377,000	0	—
Prepaid expenses and other current assets	6	−221,000	−241,000	−430,000	−5
Other long-term assets	425,000	−4	2	354,000	−7
Accrued rent receivable	−3	−4	—	—	—
Accounts payable	116,000	−556,000	−1	−2	4
Operating lease liabilities	−1	−1	−1	−335,000	0
Long-term liabilities	−79,000	77,000	−12,000	2	0
Accrued expenses and other current liabilities	−2	−2	−8	−14	12
Net cash used in operating activities	−37	−56	−82	−180	−122
Purchase of marketable securities	−101	−134	−301	−665	−1,108
Maturities of marketable securities	136	198	362	865	691
Cash received from asset disposals	432,000	866,000	—	—	—
Acquired in-process research and development	−10	−10	0	—	—
Cash received from termination of derivative financial instrument	0	605,000	0	—	—
Purchase of derivative financial instrument	0	−2	0	−1	0
Net cash provided by investing activities	25	54	41	115	−474
Proceeds from the 2024 Loan	0	86	0	70	0
Principal payments on Construction Loans	0	−83	−587,000	—	—
Proceeds from at-the-market offering, net of $0.3 million in issuance costs	7	0	—	—	—
Proceeds from exercise of stock options	853,000	365,000	0	2	2
2024 Loan agreement closing costs	−172,000	−1	0	—	—
Net cash provided by financing activities	7	2	8	72	393
Net (decrease) increase in cash, cash equivalents, and restricted cash	−4	33,000	−33	6	−203
Effect of exchange rate changes on cash, cash equivalents and restricted cash	20,000	−94,000	−201,000	−637,000	−304,000
Cash paid for interest	5	8	7	1	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro